HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.

AbstractINTRODUCTION:
Bacteremia remains a major cause of life-threatening complications in patients receiving anticancer chemotherapy. The spectrum and susceptibility profiles of causative microorganisms differ with time and place. Data from Lebanon are scarce. We aim at evaluating the epidemiology of bacteremia in cancer patients in a university hospital in Lebanon, emphasizing antibiotic resistance and risk factors of multi-drug resistant organism (MDRO)-associated bacteremia.
MATERIALS AND METHODS:
This is a retrospective study of 75 episodes of bacteremia occurring in febrile neutropenic patients admitted to the hematology-oncology unit at Makassed General Hospital, Lebanon, from October 2009-January 2012. It corresponds to epidemiological data on bacteremia episodes in febrile neutropenic cancer patients including antimicrobial resistance and identification of risk factors associated with third generation cephalosporin resistance (3GCR) and MDRO-associated bacteremia.
RESULTS:
Out of 75 bacteremias, 42.7% were gram-positive (GP), and 57.3% were gram-negative (GN). GP bacteremias were mostly due to methicillin-resistant coagulase negative staphylococci (28% of total bacteremias and 66% of GP bacteremias). Among the GN bacteremias, Escherichia coli (22.7% of total, 39.5% of GN organisms) and Klebsiella pneumoniae(13.3% of total, 23.3% of GN organisms) were the most important causative agents. GN bacteremia due to 3GC sensitive (3GCS) bacteria represented 28% of total bacteremias, while 29% were due to 3GCR bacteria and 9% were due to carbapenem-resistant organisms. There was a significant correlation between bacteremia with MDRO and subsequent intubation, sepsis and mortality. Among potential risk factors, only broad spectrum antibiotic intake >4 days before bacteremia was found to be statistically significant for acquisition of 3GCR bacteria. Using carbapenems or piperacillin/tazobactam>4 days before bacteremia was significantly associated with the emergence of MDRO (p < 0.05).
CONCLUSION:
Our findings have major implications for the management of febrile neutropenia, especially in breakthrough bacteremia and fever when patients are already on broadspectrum antibiotics. Emergence of resistance to 3GCs and, to a lesser extent, to carbapenems in GN isolates has to be considered seriously in our local guidelines for empiric treatment of febrile neutropenia, especially given that their occurrence was proven to be associated with poorer outcomes.
AuthorsRima Moghnieh, Nour Estaitieh, Anas Mugharbil, Tamima Jisr, Dania I Abdallah, Fouad Ziade, Loubna Sinno, Ahmad Ibrahim
JournalFrontiers in cellular and infection microbiology (Front Cell Infect Microbiol) Vol. 5 Pg. 11 ( 2015) ISSN: 2235-2988 [Electronic] Switzerland
PMID25729741 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Cephalosporins
Topics
  • Adolescent
  • Adult
  • Aged
  • Anti-Bacterial Agents (therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Bacteremia (drug therapy, epidemiology, etiology, microbiology)
  • Cephalosporins (therapeutic use)
  • Child
  • Child, Preschool
  • Drug Resistance, Bacterial
  • Enterobacteriaceae (drug effects, genetics, isolation & purification)
  • Febrile Neutropenia (complications, drug therapy)
  • Female
  • Gram-Negative Bacteria (drug effects, genetics, isolation & purification)
  • Gram-Negative Bacterial Infections (drug therapy, epidemiology, etiology, microbiology)
  • Humans
  • Lebanon (epidemiology)
  • Male
  • Middle Aged
  • Neoplasms (complications, drug therapy)
  • Prognosis
  • Retrospective Studies
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: